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Background
Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random
genetic aberrations related to outcome. The genetic subtype is currently detected by different
diagnostic procedures which differ in success rate and/or specificity. 
Design and Methods
We examined the potential of gene expression profiles to classify pediatric acute myeloid
leukemia. Gene expression microarray data of 237 children with acute myeloid leukemia were
collected and a double-loop cross validation approach was used to generate a subtype-predictive
gene expression profile in the discovery cohort (n=157) which was then tested for its true pre-
dictive value in the independent validation cohort (n=80). The classifier consisted of 75 probe
sets, representing the top 15 discriminating probe sets for MLL-rearranged, t(8;21)(q22;q22),
inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)-positive acute myeloid leukemia. 
Results
These cytogenetic subtypes represent approximately 40% of cases of pediatric acute myeloid
leukemia and were predicted with 92% and 99% accuracy in the discovery and independent
validation cohort, respectively. However, for NPM1, CEBPA, MLL(-PTD), FLT3(-ITD), KIT,
PTPN11 and N/K-RAS gene expression signatures had limited predictive value. This may be
caused by a limited frequency of these mutations and by underlying cytogenetics. This latter is
exemplified by the fact that different gene expression signatures were discovered for FLT3-ITD
in patients with normal cytogenetics and in those with t(15;17)(q21;q22)-positive acute
myeloid leukemia, which pointed to HOXB-upregulation being specific for FLT3-ITD+ cytoge-
netically normal acute myeloid leukemia. 
Conclusions
In conclusion, gene expression profiling correctly predicted the most prevalent cytogenetic sub-
types of pediatric acute myeloid leukemia with high accuracy. In clinical practice, this gene
expression signature may replace multiple diagnostic tests for approximately 40% of pediatric
acute myeloid leukemia cases whereas only for the remaining cases (predicted as ‘acute
myeloid leukemia-other’) are additional tests indicated. Moreover, the discriminative genes
reveal new insights into the biology of acute myeloid leukemia subtypes that warrants follow-
up as potential targets for new therapies.
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Introduction
Pediatric acute myeloid leukemia (AML) is a heteroge-
neous disease that accounts for 15-20% of the acute
leukemias in children1 and is classified according to the
WHO classification, which is based on non-random genet-
ic aberrations.2 Over the decades the outcome of pediatric
AML has improved and current overall survival rates range
from 50% to 70%.3 The most important prognostic factors
in pediatric AML are response to induction therapy and the
cytogenetic and molecular subtype of the disease.4,5
Gilliland et al. postulated that the pathogenesis of AML
requires both type I and type II mutations.6 Type II muta-
tions are often chromosomal rearrangements of transcrip-
tion factors leading to impaired differentiation of the
hematopoietic cell, such as 11q23/MLL-rearranged,
t(8;21)(q22;q22)[RUNX1-RUNXT1], inv(16)(p13q22)[CBFB-
MYH11], or t(15;17)(q21;q22) [PML-RARA]. Patients with
t(8;21)(q22;q22), inv(16)(p13q22) and t(15;17)(q21;q22)-pos-
itive AML have a favorable prognosis in contrast to MLL-
rearranged cases. Type I mutations often reflect molecular
mutation hotspots in specific genes (FLT3, KIT and NRAS,
KRAS, PTPN11 and NF1) involved in the proliferation of
hematopoietic cells.7,8 In adult and pediatric AML FLT3-
internal tandem duplications (FLT3-ITD) and KITmutations
have been correlated with an inferior outcome.9-11
In approximately 20% of pediatric AML cases no chro-
mosomal aberrations have yet been discovered. These
patients with apparent cytogenetically normal (CN) AML
are currently treated as a homogeneous group with an
intermediate risk factor. However, point mutations and
small deletions in CEBPA and NPM1 as well as partial tan-
dem duplications in MLL (MLL-PTD) are found in both
pediatric and adult CN-AML. The frequency of these
mutations is lower in children than in adults. Moreover, the
prognostic impact differs between children and adults.10,12-15
These observations highlight the genetic heterogeneity
within AML as well as between adults and children with
AML and the need for separate studies in pediatric AML to
demonstrate the value of mutations for stratification in
contemporary pediatric AML treatment protocols.
A new case of AML is currently primarily identified by
cytomorphology and immunophenotyping. Further char-
acterization needed for risk-stratification includes the
detection of chromosomal aberrations by conventional
karyotyping and molecular cytogenetics of specific genetic
lesions, for instance by fluorescence in situ hybridization
(FISH) and/or reverse transcriptase (RT) polymerase chain
reaction (PCR). However, it can be difficult to obtain a
karyogram since this requires successful induction of in
vitro cellular proliferation to obtain metaphases for analysis
of chromosomal changes. In addition, FISH and RT-PCR
procedures may also yield inconclusive results, for example
due to poor interphase preparations (FISH), limitations in
signal detection (FISH), sub-clonality (FISH and RT-PCR)
and sequence variations in probe/primer-hybridizing
regions (FISH and RT-PCR). 
Microarray-based gene expression profiling studies
showed that pediatric and adult AML can be accurately
classified into cytogenetically distinct subtypes.16-20 In the
Microarray Innovations-in-LEukemia (MILE) study, gene
expression profiles accurately classified over 3000 cases
with acute and chronic leukemia.21
We recently showed that a double-loop cross-validation
classification approach yielded a highly stable and accurate
classifier with high predictive value for subtypes of pedi-
atric acute lymphoblastic leukemia in both the cross-vali-
dation cohort as well as in a totally independent cohort of
pediatric ALL.22 In the current study we used this double-
loop cross-validation method to determine whether gene
expression signatures can predict prognostically relevant
specific cytogenetic subtypes (11q23/MLL-rearranged,
t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22),
t(7;12)(q36;p13) and CN-AML) as well as cases with
molecular aberrations in NPM1, CEBPA, FLT3-ITD, N/K-
RAS, KIT and PTPN11 in pediatric AML.
Design and Methods
Patients
Viable frozen bone marrow or peripheral blood samples from
237 children with de novo AML, 33 with relapsed and 8 with sec-
ondary AML were provided by the Dutch Childhood Oncology
Group, ‘Berlin-Frankfurt-Münster’ AML Study Group, Czech
Pediatric Hematology and St. Louis Hospital in Paris, France.
Informed consent was obtained from patients, after Institutional
Review Board approval according to national law and regulations.
Leukemic cells were isolated by sucrose density centrifugation
and non-leukemic cells were eliminated as previously described.23
All processed samples contained more than 80% leukemic cells,
as determined morphologically using cytospins stained with May-
Grünwald-Giemsa (Merck, Darmstadt, Germany). Subsequently,
at least 5×106 leukemic cells were lysed in Trizol reagent (Gibco
BRL, Life Technologies, Breda, the Netherlands). Genomic DNA
and total RNA were isolated according to the manufacturer’s pro-
tocol, with minor modifications.24
Cytogenetics 
Leukemic samples were routinely investigated for cytogenetic
aberrations by standard chromosome-banding analysis, and
screened, by the above mentioned study groups, for recurrent
non-random genetic aberrations characteristic of AML as
described by the WHO 2008 classification of myeloid neoplasms
and acute leukemia,2 including MLL-rearrangements,
inv(16)(p13q22), t(8;21)(q22;q22) and t(15;17)(q21;q22), using RT-
PCR and/or FISH. In the case of incomplete data, the Erasmus MC
group performed RT-PCR to detect inv(16)(p13q22),
t(8;21)(q22;q22) and t(15;17)(q21;q22) and split-signal FISH to
detect rearrangements of the MLL-gene using standardized
primers and probe combinations, as previously described.25,26 In
three cases, predicted as MLL-rearranged AML, screening for an
MLL-rearrangement was performed with long-distance inverse
(LDI) PCR as previously described.27 In addition, all patients under
the age of 18 months were screened for t(7;12)(q36;p13) by FISH.
The probes used were five cosmid clones covering the break-
points in the ETV6 gene and a PAC clone (RP5-1121A15) contain-
ing the HLXB9 gene, as previously described.28 
Mutation analysis
Samples were screened for hotspot mutations in NPM1,
CEPBA, FLT3-ITD, NRAS, KRAS, PTPN11, KIT and MLL-PTD, as
previously described.7,29-32 If positive for MLL-PTD, this was con-
firmed by a multiplex ligation-dependent probe amplification
(MLPA) analysis (MRC Holland, Amsterdam, the Netherlands).
The reaction mix for MPLA-analysis contained probes for exon 2
to 13 of MLL for MLL-PTD detection and exon 17 of MLL as an
internal control. A probe in the serpinB2 gene was used as an exter-
nal control.33 Data were analyzed using GeneMarker v1.5
(Softgenetics, State College, USA).  
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Microarray
The integrity of total RNA was checked using the Agilent
2100 Bio-analyzer (Agilent, Santa Clara, USA). cDNA and
biotinylated cRNA were synthesized and hybridized to the
Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix,
Santa Clara, USA) according to the manufacturer’s guidelines.
Data were acquired using ‘expresso’ (Bioconductor package
‘Affy’), and probe-set intensities were normalized using the vari-
ance stabilization normalization procedure (Bioconductor pack-
age ‘VSN’) in the statistical data analysis environment R, version
2.2.0. The original data files have been submitted to the GEO
database (GSE17855).
Statistics
To find signatures for the different cytogenetic and molecular
subtypes an empirical Bayes linear regression model was used to
compare samples from each group to all other samples.34 This
model takes advantage of the large number of probe sets to yield
better estimates for the gene-specific standard error, producing
more powerful tests for differential expression even if small
sample sizes are involved. Moderated t-statistics P values were
corrected for multiple testing using the false discovery rate (FDR)
method defined by Benjamini and Hochberg.35 The top 50 most
significant probe sets for each subtype were used as a starting
point to construct the classifier.
The construction of the classifier
Samples were divided at random into a discovery cohort of
157 cases that were used for the double-loop cross validation
approach and an independent cohort of 80 cases, which was
only tested once and served as a true independent validation
cohort. In all following 100 cycles of the double-loop cross-val-
idation approach, the sample distribution of the discovery
cohort reflected the distribution of cytogenetic subtypes as
seen in the total cohort of 237 cases. The double-loop cross-
validation method was used to build a support-vector
machine-based classifier predictive for the known cytogenetic
subtypes of pediatric AML. This approach avoids over-fitting
of gene expression profiling data36 and has proven to yield a
stable classifier with high accuracy to predict subtypes of pedi-
atric acute lymphoblastic leukemia, as we previously
showed.22 The double-loop cross-validation method was only
applied to the discovery cohort of 157 cases. This consists of an
inner loop containing two-thirds of cases in which the minimal
number of probe sets yielding the highest prediction sensitivity
is being determined (100 iterations for each selected number of
probe sets) and an outer loop containing the remaining one-
third of cases serving to validate the obtained results from the
inner loop (also 100 iterations per list of probe sets) (Online
Supplementary Figure S1).
In each of 100 runs of the inner loop, patients were randomly
assigned to the inner-training (9/10) and inner-test (1/10) group
(10-fold cross-validation). To start, the top 50 probe sets most
discriminative for each subtype were selected by rank of P val-
ues obtained by applying an empirical Bayes linear regression
model (LIMMA) to the inner-training group. These probe sets
were used to construct a support vector machine-based classi-
fier which was then tested for predictive sensitivity on the
inner-test group of the remaining 1/10 of cases (100 iterations).
Next, the minimum number of probe sets that optimally clas-
sified the patients in the inner loop was obtained by backwards
selection starting with 250 probe sets (50 probe sets x 5 sub-
types) using a global test for ranking the significance of probe
sets in each iteration in order to reduce multiple testing errors,
as previously described.22 The optimal number of probe sets
determined in the inner loop was used to construct a classifier
for which the median sensitivity was estimated via 3-fold
cross-validation by applying the trained classifier to the
remaining one-third of the cases of the outer loop (100 itera-
tions; Online Supplementary Figure S1). The final gene expres-
sion classifier, trained on all 157 cases in the discovery cohort,
was used to determine the prediction accuracy in the inde-
pendent group of 80 cases (Online Supplementary Figure S1).
The same approach was used to select probe sets predictive
for the most frequent molecular aberrations, i.e. NPM1,
CEBPA, MLL-PTD, FLT3-ITD, KIT, and combined mutations in
the RAS-pathway (NRAS, KRAS and PTPN11), Since NPM1,
CEBPA and MLL-PTD were mutually exclusive from the other
cytogenetic subgroups, these abnormalities could be simulta-
neously included in one model together with the known cyto-
genetic subgroups, for which the prediction accuracy was esti-
mated as described above. In addition, we performed an analy-
sis in which the most discriminative probe sets for type I muta-
tions in FLT3-ITD, KIT and RAS-pathway were identified, after
adjusting for the underlying cytogenetic aberrations.
Software
R (version 2.2.0 and version 2.5.0) and the R packages affy,
vsn, e1071, globaltest, limma, multtest and marray were used to
run the above-mentioned analyses.34,37-41 Hierarchical clustering
analysis was performed in Genemaths XT (Applied Maths,
Austin, USA).
Results
Patients’ characteristics
Gene expression profiles were generated from 237
newly diagnosed pediatric AML cases. Non-random
cytogenetic subgroups of pediatric AML with a suffi-
cient number of cases were included, i.e. MLL-
rearranged AML, t(8;21)(q22;q22), inv(16)(p13q22),
t(15;17)(q21;q22) and CN-AML. In addition, seven
t(7;12)(q36;p13)-positive infant AML cases were includ-
ed (Table 1). For the other cytogenetic groups, e.g.
t(6;9)(p23;q34) (n=7), monosomy 7 (n=4), trisomy 8
(n=1) and complex karyotype (n=11), no significant dis-
criminative genes were found and these cases were,
therefore, combined into a single group annotated with
‘remaining cytogenetics’. No karyotype was available
for 25 cases but since these cases were negative for MLL-
rearrangements, t(8;21)(q22;q22), inv(16)(p13q22),
t(15;17)(q21;q22) and t(7;12)(q36;p13), these cases were
included in the ‘unknown other cytogenetics’ category.
Definition of subgroups
Using an empirical Bayes linear regression model many
discriminative probe sets, with high statistical significance
(P<1.0-08), were found for MLL-rearranged, t(8;21)(q22;q22),
inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)-
positive AML (Online Supplementary Table S2). In contrast,
only a limited number of discriminative probe sets were
found to be significant at lower P value (P<1.0-04) for CN-
AML, cases with remaining genetic aberrations or
unknown other cytogenetics (Online Supplementary Table
S2). Hereafter, this mixed group is referred to as the ‘AML-
other’ group. Based on an equal distribution of these
groups, the overall cohort was divided into a discovery
cohort (n=157) to construct the classifier and an independ-
ent validation cohort (n=80).
Gene expression signatures in pediatric AML
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Probe set selection for classifier estimated with 
the discovery cohort
The classifier was constructed by selecting the most sta-
tistically significantly discriminative probe sets for each of
the five cytogenetic subtypes: MLL-rearranged,
t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22) and
t(7;12)(q36;p13)-positive AML. A double-loop cross valida-
tion approach was used that also included a backward
selection procedure to keep the number of probe sets need-
ed for most accurate classification to a minimum in order
to avoid over-fitting of data, as previously described.22 In
the inner-loop the minimum number needed for the high-
est predictive sensitivity of 100% was determined to be 75
probe sets (Table 2, Online Supplementary Table S3), i.e. 15
probe sets per cytogenetic subtype, whereas randomly
selected probe sets only yielded a median sensitivity of
60% (Online Supplementary Figure S2). Some of these probe
sets represented the same gene, e.g. four probe sets pre-
sented RUNX1T1 for the t(8;21)(q22;q22) subtype (Table
2). The constructed classifier took into account the expres-
sion levels of all 75 probe sets, including the 60 probe sets
that were not selected for a particular subtype. The classi-
fier built with these 75 probe sets yielded a median accura-
cy of 92% in the outer loop. Notably, all inv(16)(p13q22),
t(15;17)(q21;q22) and t(7;12)(q36;p13)-positive cases were
correctly predicted in each of the 100 iterations (100% sen-
sitivity, specificity, positive predictive value and negative
predictive value) (Table 3A).  
Hierarchical clustering showed that the cytogenetic sub-
types formed distinct clusters according to the gene expres-
sion signature using these 75 probe sets (Figure 1A, Online
Supplementary Table S3). Only three AML-other patients
were misclassified as having MLL-rearranged AML. In
these cases, MLL involvement could not be confirmed with
FISH, but LDI-PCR revealed that all three samples did
indeed harbor an MLL-rearrangement (Online
Supplementary Table S4). These three samples were, there-
fore, included as true positive MLL-rearranged cases in the
construction of the final classifier in the discovery cohort.
As expected, including these cases as MLL-rearranged
AML improved the diagnostic values of the 3-fold cross
validation in the outer loop (Table 3B).
Independent validation of the classifier
The true accuracy of the classifier was tested in the inde-
pendent validation cohort of 80 patients. The true sensitiv-
ity, specificity, positive predictive value, negative predictive
value and accuracy in this validation cohort was 98%,
B.V. Balgobind et al.
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Table 1. Cytogenetic and molecular characteristics of the pediatric
acute myeloid leukemia patients in this study.
                                               Discovery     Validation             Total
                                                   cohort           cohort             (n=237)
                                                  (n=157)          (n=80)                    
                                                N        %         N         %          N         %
Cytogenetic subtypes
MLL-rearrangements                    31         20          16         18           47          20
t(8;21)(q22;q22)                            18         11          10         11           28          12
inv(16)(p13q22)                             17         11          10         11           27          11
t(15;17)(q21;q22)                          14          9            5           6            19           8
t(7;12)(q36;p13)                             5           3            2           2             7            3
AML-other#
CN-AMLa                                           24         15          15         17           39          16
Remaining cytogeneticsa              33         21          12         14           45          19
Unknown other cytogeneticsa     15         10          10         11           25          11
Molecular subtypes
NPM1b                                                9           5            8           9            18           7
MLL-PTDb                                          3           2            3           3             6            2
CEBPAb                                              10          6            6           7            16           6
FLT3-ITD                                          30         18          18         21           48          19
KIT                                                     12          7            6           7            18           7 
N/KRAS                                              23         14          18         21           41          16
PTPN11                                              4           2            1           1             5            2
#Including three cases predicted as MLL-rearranged AML and confirmed by LDI-PCR;
aTogether forming the AML-other subtype used throughout this classification study. All
samples were negative for MLL-rearrangements, t(8;21)(q22;q22), inv(16)(p13q22),
t(15;17)(q21;q22) and t(7;12)(q36;p13). bThese subtypes were only observed in sam-
ples in the AML-other subtype.
Table 2. Overview of discriminative genes used in the classification of pediatric acute myeloid leukemia.
MLL-rearranged AML                   t(8;21)(q22;q22)                          inv(16)(p13q22)                    t(15;17)(q21;q22)                   t(7;12)(q36;p13)
WHAMML1 (2)                                       RUNX1T1 (4)                                         MYH11 (3)                                        HGF (2)                                        TP53BP2
ITM2A (2)                                                   IL5RA (2)                                             LPAR1 (2)                                       STAB1 (2)                                     chr14q23.1
C10orf140 (2)                                          POU4F1 (2)                                            NT5E (2)                                     FAM19A5 (2)                                     DYX1C1
C10orf114                                                  SIPA1L2 (2)                                                NRP1                                               ANXA8                                             EDIL3
CES1                                                                  TRH                                                    TM4SF1                                           LGALS12                                          LIN28B
TBC1D12                                                        PGAM5                                                    LRP4                                                 SIX3                                              BAMBI
PHACTR3                                                       SIPA1L2                                                   CLIP3                                              PGBD5                                              MAF
LOC84989                                                   CACNA2D2                                                 MN1                                               C2orf82                                         FAM171B
ZNF91                                           Unknown (chr8q21.3) (2)                                  SPARC                                              FGF13                                             AGR2
ZNF329                                                                                                                             AK5                                                 MST1                              Unknown (chr2q14.3)
Unknown (chr13q22.1)                                                                               Unknown (chr17p13.3)                            TNFRSF4                                         CRISP3
Unknown(chr10p12.31)                                                                                                                                                     IGDCC4                                           MNX1
                                                                                                                                                                                                                                                        CTTNBP2
                                                                                                                                                                                                                                                           KRT72
                                                                                                                                                                                                                                                            MMP
In parentheses the number of probe sets representing the same gene. In total 75 probe sets were included in the classifying model, which represents 59 unique genes. 
100%, 100%, 97% and 99%, respectively (Table 3C). Only
one MLL-rearranged AML case was misclassified as AML-
other (Table 4). Hierarchical cluster analysis also demon-
strated the discriminative value of the selected probe sets
in the independent validation cohort (Figure 1B). At this
point, only patients at initial diagnosis of AML had been
included. Next, we addressed whether the classifier was
also suitable for predicting the subtype of 33 relapsed and
eight secondary AML cases. All nine MLL-rearranged cases
(3 secondary and 6 relapsed AML cases), all five
t(8;21)(q22;q22) relapsed cases and all 27 other relapsed
and secondary AML cases were correctly predicted by our
classifier (Online Supplementary Table S5).
Comparison with other gene expression profiles in pedi-
atric and adult acute myeloid leukemia
Ross et al. demonstrated that children with AML could
be classified using gene expression profiles generated by
Affymetrix U133A microarrays containing 22,283 probe
sets.17 An overall accuracy of 93% was achieved using 150
probe sets to classify MLL-rearranged AML,
t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22) and
acute megakaryoblastic leukemias (M7). In that study,
t(7;12)(q36;p13)-positive AML cases were not included.
The 150 probe sets of Ross et al. were used to construct a
classifier in our discovery cohort which was then applied
to the independent validation cohort, exactly as done for
testing our own 75 probe set-based classifier. Five out of 80
patients were misclassified, yielding an overall predictive
accuracy of 94% for Ross’ set compared to 99% for the 75
probe sets selected in this study (Online Supplementary Table
S6). The misclassified cases included two MLL-rearranged
and two t(7;12)(q36;p13)-positive cases which were
assigned to the AML-other category and one AML-other
case which was predicted as an MLL-rearranged case.
Since only 40 out of our 75 probe sets were present on the
U133A microarray used by Ross et al., the reciprocal com-
parison of our list of selected probe sets on Ross’ dataset
was not informative. 
Valk et al. described 16 different subgroups in adult AML
using 2,856 probe sets present on Affymetrix U133A
microarrays.18 A classifier built with these 2,856 probe sets
resulted in an overall accuracy of 94% when applied to our
independent pediatric validation cohort (Online
Supplementary Table S6). Three MLL-rearranged cases and
one t(7;12)(q36;p13)-positive case were misclassified as
AML-others. One AML-other patient was misclassified as
having MLL-rearranged AML.
Potential type II molecular aberrations: NPM1, CEBPA
and MLL-PTD 
Mutations in NPM1 and CEBPA and partial tandem
duplications in MLL (MLL-PTD) might be considered as
various type II mutations and were only observed in sam-
ples belonging to the AML-other group (Online
Supplementary Table S7). Moreover, these molecular abnor-
malities were mutually exclusive reflecting heterogeneity
Gene expression signatures in pediatric AML
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Table 3. Diagnostic test values for the classification of pediatric acute myeloid
leukemia by a gene expression signature consisting of 75 probe sets.
Discovery cohorta 3-fold cross-validation (100 iterations)
A                           % sensitivity   % specificity    % PPV        % NPV       % accuracy
MLL-rearranged               80                       95                  83                  95                      93
                                        (70-90)              (95-98)        (78-89)        (93-97)            (92-95)
t(8;21)(q22;q22)             100                     100                100                100                   100
                                       (83-100)          (100-100)    (100-100)     (98-100)          (98-100)
inv(16)(p13q22)             100                     100                100                100                   100
                                      (100-100)         (100-100)    (100-100)    (100-100)        (100-100)
t(15;17)(q21;q22)           100                     100                100                100                   100
                                      (100-100)         (100-100)    (100-100)    (100-100)        (100-100)
t(7;12)(q36;p13)             100                     100                100                100                   100
                                      (100-100)         (100-100)    (100-100)    (100-100)        (100-100)
AML-other                        92                       92                  92                  93                      92
                                        (92-96)              (88-96)        (88-96)        (92-96)            (90-94)
All groups                          92                       92                  93                  92                      92
                                        (88-96)              (92-96)        (92-96)        (88-96)            (90-94)
Discovery cohorta 3-fold cross-validation (100 iterations)
B                          % sensitivity   % specificity    % PPV        % NPV       % accuracy
MLL-rearranged#             90                       97                  92                  98                      96
                                       (82-100)           (97-100)      (89-100)      (95-100)           (94-98)
t(8;21)(q22;q22)             100                     100                100                100                   100
                                       (83-100)          (100-100)    (100-100)     (98-100)          (98-100)
inv(16)(p13q22)             100                     100                100                100                   100
                                      (100-100)         (100-100)    (100-100)    (100-100)        (100-100)
t(15;17)(q21;q22)           100                     100                100                100                   100
                                      (100-100)         (100-100)    (100-100)    (100-100)        (100-100)
t(7;12)(q36;p13)             100                     100                100                100                   100
                                      (100-100)         (100-100)    (100-100)    (100-100)        (100-100)
AML-other                         96                       94                  94                  96                      96
                                       (96-100)             (89-96)        (88-96)       (96-100)           (92-98)
All groups                          94                       96                  96                  94                      96
                                        (89-96)             (96-100)      (96-100)       (88-96)            (92-98)
(A) and (B) aValues represent the median  and 25th-75th percentiles (in parentheses) obtained 
by 3-fold cross-validation using the discovery cohort of 157 cases (100 iterations). 
#In contrast to Table 3A, the MLL-rearranged category in Table 3B now includes the three novel MLL-
rearranged cases that were predicted by gene expression profiling and 
confirmed by LDI-PCR.
Validation cohort  independent validation group, N=80
C                          % sensitivity   % specificity    % PPV        % NPV       % accuracy
MLL-rearranged               94                      100                100                 98                      99
t(8;21)(q22;q22)             100                     100                100                100                   100
inv(16)(p13q22)             100                     100                100                100                   100
t(15;17)(q21;q22)           100                     100                100                100                   100
t(7;12)(q36;p13)             100                     100                100                100                   100
AML-other                       100                      98                  97                 100                     99
All groups                          98                      100                100                 97                      99
Table 4. Prediction of the classifier on the independent validation cohort. 
                                      Subtype according to cytogenetic screening
                                   MLL    t(8;21)   inv(16)    t(15;17)   t(7;12)    AML
                                                                                                         Other
SVM predicted subtype
MLL-rearranged               15             0               0                 0                0              0
t(8;21)(q22;q22)               0             10              0                 0                0              0
inv(16)(p13q22)               0              0              10                0                0              0
t(15;17)(q21;q22)             0              0               0                 5                0              0
t(7;12)(q36;p13)               0              0               0                 0                2              0
AML-Other                         1              0               0                 0                0             37
The sensitivity, specificity, positive predictive value, negative predictive value and accu-
racy were 98% (51/52), 100% (37/37), 100% (52/52), 97% (37/38) and 99% (79/80),
respectively.
Table 5. Diagnostic test values for the prediction of mutations in NPM1,
CEBP· and MLL-PTD for the independent validation cohort by the gene
expression signature consisting of 45 probe sets (A) and for the prediction
of type I molecular subtypes for the independent validation cohort by the
gene expression signature consisting of 30 probe sets (B).
Validation cohort independent validation group, N=80
A                         % sensitivity  % specificity   % PPV        % NPV       % accuracy
NPM1                                 13                       99                  50                  91                      90
MLL-PTD                            0                       100                ND                 96                      96
CEBPA                               33                      100                100                 95                      95
Remaining cases            98                       18                  82                  75                      81
All groups                         18                       98                  75                  82                      81
Validation cohort independent validation group, N=80
B % sensitivity   % specificity    % PPV        % NPV       % accuracy
FLT3-ITD 72                      100                100                 93                      94
KIT 33                       99                  66                  95                      94
Remaining cases 89                       63                  86                  94                      88
All groups 63                       89                  94                  86                     88 
among the AML-other cases. For CEBPA, 852 probe sets
were found to be statistically discriminative between
mutated and germ-line cases whereas only 12 probe sets
were found to be discriminative for MLL-PTD at the same
cut-off value of P<0.05 (FDR-corrected; Online
Supplementary Table S8). Three-fold cross validation with
the top 15 most discriminative probe sets for mutations in
NPM1, CEBPA and MLL (i.e. MLL-PTD) revealed a median
sensitivity and accuracy in the outer loop of 43% and 92%,
respectively, and sensitivity, specificity, positive predictive
value, negative predictive value and accuracy of 18%,
98%, 75%, 82% and 81%, respectively, in the independent
validation cohort (Table 5A, Online Supplementary Table S9).
In the independent validation cohort 7/8 cases with an
NPM1 mutation, 4/6 cases with a CEBPA mutation and all
three MLL-PTD cases were misclassified. Moreover, when
adding these three molecular subtypes to the previously
used five cytogenetic subtypes, the accuracy of 99% based
on the five cytogenetic subtypes dropped to 78% in the
validation cohort (Online Supplementary Table S10). All mis-
classified cases were assigned to the AML-other category.
Type I mutations: FLT3-ITD, KIT, N/K-RAS and PTPN11
Internal tandem duplication in FLT3 (FLT3-ITD), muta-
tions in KIT and mutations in genes involved in the RAS-
pathway [NRAS (n=34), KRAS (n=7) and PTPN11 (n=5)]
were observed in 44% of all cases. In contrast to FLT3-ITD
and KIT aberrations, no discriminative probe sets were
found for N/K-RAS and only a limited number for PTPN11
(Online Supplementary Table S8). Combining the aberrations
in the RAS-pathway into one group still did not identify
discriminative probe sets. We, therefore, only included
FLT3-ITD and KIT into a classification model for the pre-
diction of type I mutations. However, the 30 most discrim-
inative probe sets for these subtypes resulted in a classifier
with limited predictive value. The highest predictive values
were found for FLT3-ITD, with a positive predictive value
and negative predictive value of 100% and 93%, respec-
tively (Table 5B, Online Supplementary Table S11). Inclusion
of the top 15 discriminative probe sets for aberrations in
the RAS-pathway (although with P>0.05) did not result in
prediction of this subtype (Online Supplementary Table S12). 
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Figure 1. Hierarchical clustering of the cytogenetic subtypes of pedi-
atric AML by gene expression profiling. (A) Hierarchical clustering of
157 patients in the discovery cohort by gene expression signature
derived from 75 classifying probe sets (Online Supplementary Table
S2). (B) Validation of the gene expression pattern in 80 patients of the
independent validation cohort (C) MLL-rearranged AML cases do not
separate into distinct clusters based on similarity in expression pattern
related to the translocation partner using the 75 classifying probe sets.   
Although a large number of discriminative genes were
found for FLT3-ITD (Online Supplementary Table S8), many
probe sets were similar to those found for t(15;17)(q21;q22)
instead of being specific for FLT3-ITD. This is in line with
the fact that FLT3-ITD is often found in t(15;17)(q21;q22)-
positive cases. To correct for these cytogenetic effects, we
applied the Bayes linear regression model while adjusting
for cytogenetic subtype. In this multivariate analysis,
unique gene expression signatures specific for FLT3-ITD-
positive cases were found that differ between
t(15;17)(q21;q22)-positive and CN-AML cases (Figure 2,
Online Supplementary Table S13). Specifically, the genes of
the HOXB cluster were over-expressed in all patients with
a FLT3-ITD-positive CN-AML and not in FLT3-ITD-
negative CN-AML or t(15;17)(q21;q22) patients (Figure 2,
Online Supplementary Figure S3). The same multivariate
approach for KIT and RAS-pathway mutations did not
result in cytogenetic subtype-specific gene expression sig-
natures.
When adding the 15 probe sets discriminative for
t(15;17)(q21;q22)/FLT3-ITD and  the nine most discrimina-
tive probe sets [the 6 other probe sets showed overlap with
the t(15;17)(q21;q22) subgroup] for CN-AML/FLT3-ITD
from the multivariate analysis to our classifier, we still
could not accurately predict all FLT3-ITD cases. Although
numbers were small in these subgroups, the accuracy in
the independent validation cohort dropped to 86% due to
misclassification of cases, especially CN-AML/FLT3-ITD
cases (Online Supplementary Table S14). 
Discussion
Cytogenetic aberrations have prognostic value in pedi-
atric AML and, hence, genetic subtypes are used for risk
stratification in most current pediatric AML treatment pro-
tocols and are part of the current WHO classification of
myeloid neoplasms and acute leukemia.2 In the present
study we explored the possibility of microarray-based
gene expression profiling to identify the cytogenetic and
molecular subtypes in pediatric AML. A gene expression
signature of 75 probe sets predicted the most important
non-random cytogenetic aberrations in an independent
pediatric AML cohort with 99% accuracy and a positive
and negative predictive value of 100% and 97%, respec-
tively. In addition, unique gene-expression signatures were
found for FLT3-ITD AML which differed between cytoge-
netic subtypes.
Gene expression profiling has been shown to predict the
major cytogenetic subgroups in both pediatric and adult
AML.17-19 The sensitivity and specificity of such signatures
should be addressed in an independent and representative
cohort, since microarray data analysis can easily result in
over-interpretation of data.42 Recently, the MILE study
group, using an independent validation cohort of 1,152
cases, robustly showed that gene expression profiles can be
used to classify different types of (mainly adult) myelodys-
plastic syndrome and chronic and acute leukemia cases
into known cytogenetic subtypes.21 This study mainly
included adult cases (whose disease may differ in etiology
from that of children) and did not address the prediction of
molecular abnormalities (e.g. FLT3-ITD and RAS muta-
tions) by gene expression profiles. In the present study we
specifically addressed the value of gene expression profiles
for prediction of and classification based on cytogenetic
and molecular subtypes of children at initial diagnosis of
AML. We previously showed the predictive value of a dou-
ble-loop cross-validation approach to select classifying
probe sets and validated these using an independent vali-
dation cohort in pediatric ALL,22 and therefore used the
same unbiased approach in this childhood AML study.
In the present study we identified a gene expression sig-
nature of 75 probe sets, representing 15 probe sets for each
subgroup, to predict MLL-rearranged, t(8;21)(q22;q22),
inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)
positive AML. When applied to our independent validation
cohort the sensitivity, specificity, and negative and positive
predictive values of this signature were 98%, 100%, 100%
and 97%, respectively. The prediction of MLL-rearranged
AML, in particular, was better with the newly selected
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Figure 2. Hierarchical clustering of FLT3-ITD
positive cases in t(15;17)(q21;q22) and CN-
AML. Hierarchical clustering for FLT3-ITD in
t(15;17)(q21;q22) and CN-AML based on 126
probe sets selected by multivariate analysis
including molecular and cytogenetic subtypes
(Online Supplementary Table S12). Highlighted
boxes represent probe sets for FLT3-ITD and the
specific cytogenetic subtype. The HOXB cluster
probe sets are represented in yellow.
probe sets than with the previously used probe sets com-
piled by Ross et al.17 and Valk et al.18 Since 35 probe sets
were not present on the Affymetrix U133A microarrays
used in both of the former studies, these new probe sets
are perhaps decisive for correct prediction of cytogenetic
subgroups in pediatric AML. 
The 75 probe sets harbored probe sets for genes involved
in the specific translocations, e.g. the probe sets for
RUNX1T1/ETO were highly discriminative for
t(8;21)(q22;q22), those for MYH11 for inv(16)(p13q22) and
the probe set for HLXB9 for t(7;12)(q36;p13). The high
expression of these probe sets is probably related to specif-
ic hybridization to the fusion transcript, as suggested by
Kohlmann et al.43 Remarkably, six out of 15 probe sets dis-
criminative for MLL-rearranged AML (Table 2) were locat-
ed in non-protein coding regions of the genome. Four of
these probe sets were located in a relative small (<40 Kb)
region on chromosome 10. This is of interest, since nowa-
days these regions cannot be considered as junk DNA, but
might be involved in the regulation of other genes, such as
miRNA.44
In parallel to the present study we found that expression
of one of the discriminative genes for MLL-rearranged
AML, i.e. brain and reproductive organ-expressed gene
(BRE), was highly associated with a favorable prognosis in
cases with t(9;11)(p22;q23). Functional studies with BRE
did not reveal that the proliferation, apoptosis or sensitivity
towards drugs was altered upon re-expression in AML
cells, suggesting that BRE itself has no anti-proliferative
function.45 Besides BRE, other new prognostic genes have
recently been identified using gene expression profiling. An
example is the angiogenic factor VEGFC, for which a high
level of expression was associated with an unfavorable
clinical outcome in both childhood and adult AML.46
According to gene expression profiling, the EVI1 gene had
no prognostic impact in children with AML, in contrast to
the situation in adults, emphasizing the need for separate
analysis of pediatric and adult AML.47 In adult AML gene
expression profiling showed that high expression of ERG
and MN1 was related to outcome, although their role in
malignant transformation remains unknown.48,49 More
recently a unique gene expression signature was identified
for the prognostically relevant mutation in IDH2, which
may help to unravel the role of IDH2 in the biology of
AML.50 Thus, gene expression profiling identifies new
genes linked to subtypes and/or prognosis of AML and
may provide important information about the biology of
disease when further functional studies have been per-
formed. This knowledge is needed for the rational devel-
opment and optimization of treatment protocols; more-
over, affected genes and pathways may serve as targets for
new therapies (‘targeted therapy’).
Three AML-other cases that were negative by MLL-split
signal FISH were initially thought to be misclassified as
MLL-rearranged AML. However, more detailed analysis of
the MLL-gene using LDI-PCR confirmed that the MLL-
gene was indeed rearranged, indicating the higher sensitiv-
ity of our gene expression signature than the routine diag-
nostic FISH procedure in the detection of MLL-rearranged
cases. Cryptic MLL-rearrangements can also be detected
using single nucleotide polymorphism (SNP)-array plat-
forms e.g. t(6;11)(q27;q23).51,52 These finding illustrate the
high potential of advanced methods, such as gene expres-
sion profiles, LDI-PCR and SNP-arrays, for detecting
rearrangements of the MLL gene in clinical AML samples.
The cytogenetic subgroups that could be correctly pre-
dicted in our study represented approximately 40% of
the pediatric AML cases (Online Supplementary Table S1).
The remaining patients in this study had CN-AML or
cytogenetic aberrations other than the five cytogenetic
subgroups tested in this study. Recently the subgroup
with CN-AML has been further characterized by recur-
rent molecular aberrations in NPM1, CEBPA and MLL (-
PTD). The heterogeneity of pediatric AML is further
illustrated by molecular aberrations detected in different
cytogenetic subgroups, i.e. FLT3-ITD, KIT and mutations
in the RAS-pathway. Our results show a less accurate
prediction of these molecular aberrations by gene expres-
sion signatures compared to signatures predictive for
cytogenetic subtypes, as was also observed in adult
AML.19,53 Only FLT3-ITD could be predicted with a high
negative predictive value (93%) and positive predictive
value (100%) in the independent validation cohort, but
showed lower sensitivity, as described in adult AML
cases with FLT3-ITD.54 The low predictive value for the
molecular subtypes including mutations in NPM1, MLL-
PTD, KIT and PTPN11 can be explained by the limited
number of discriminative probe sets found for each of
these aberrations (Online Supplementary Table S8 versus
Online Supplementary Table S2). This may be because of
both limited sample size for each molecular subtype and
underlying cytogenetic lesions that have a differential
effect on gene expression signatures. A limited sample
size itself does not, per se, hamper the accuracy of classi-
fication if the number of statistically significant probe
sets and the fold-change in expression levels of discrimi-
native probe sets is relatively high (exemplified by the
high accuracy at predicting t(7;12)(q36;p13)-positive
cases despite only five cases being included in the discov-
ery cohort, Online Supplementary Table S2). However, in
combination with heterogeneity in underlying cytoge-
netic abnormalities (or other genetic lesions) the number
of highly discriminative probe sets becomes limited
when sample size is also limited. 
Since some of these mutations are not mutually exclu-
sive or are restricted to distinct cytogenetic subtypes, we
also selected discriminative probe sets for FLT3-ITD using
a multivariate approach including cytogenetic subtype. For
the other molecular subtypes probe sets could not be iden-
tified in a multivariate setting, presumably because of the
limited frequency of occurrence of these mutations.
Moreover, overlapping signaling pathways between sub-
groups, no effect of the mutation on transcript level, or dif-
ferent mutations per gene can make it difficult to predict
these molecular aberrations correctly by gene expression
profiles.15,55
Depending on the cytogenetic background, specific
genetic aberrations may play different roles in the leuke-
mogenesis of pediatric AML. Interestingly, the genes of the
HOXB cluster were over-expressed in all patients with a
FLT3-ITD positive CN-AML, but not in those with a FLT3-
ITD-positive t(15;17)(q21;q22), which is in concordance
with differences in prognostic relevance between these
two subgroups. In adult AML, some of these HOXB genes
were also identified as discriminating genes for patients
with a FLT3-ITD.19 In pediatric AML, HOXB up-regulation
has been correlated with NPM1 mutations in CN-AML.56
Here we show that HOXB over-expression is not restricted
to NPM1-mutated cases, but is also found in all patients
with FLT3-ITD-positive CN-AML. 
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In conclusion, a specific gene expression signature exist-
ing of 75 probe sets could accurately identify five cytoge-
netic subgroups in pediatric AML. Molecular aberrations
were hard to predict, which could be due to the low fre-
quency of some of these aberrations and/or gene expres-
sion signatures being affected by the underlying cytogenet-
ic abnormality. It remains to be determined whether
underlying but yet unknown genetic aberrations in the
remaining cases of AML will result in distinct gene expres-
sion patterns that can be used for classification.
Classification by gene expression profiling may reduce the
number of cases for which multiple diagnostic procedures
(cytomorphology, FISH, RT-PCR, karyotyping) are per-
formed by at least 40%. In order to use gene expression
signatures as a new diagnostic tool, prospective studies are
needed that determine the feasibility of obtaining suffi-
cient high-quality RNA for successful gene expression pro-
filing in clinical practice. Importantly, gene expression pro-
files may give more insight into the biology and the patho-
physiology of the different subtypes of AML which may
then point to new ways to treat these patients more effec-
tively.
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